PLI Technologies

PLI Technologies develops and applies an innovative, patented platform for uniform labelling of compounds with stable, non-radioactive carbon-13, nitrogen-15 and deuterium isotopes. The technology works across a wide range of prokaryotic and eukaryotic species and supports cost-effective production of labelled biomolecules, from small metabolites to larger proteins, including protein therapeutics and drug targets such as GPCRs. The company offers labelled cell biomass, extracts and purified compounds, along with services including stable-isotope labelling, membrane protein labelling, structure–function studies and non-invasive analysis.

PLI Technologies also works in life sciences and health research, supporting applications such as three-dimensional structure determination and in silico drug design. Its multi-species screening and FT-IR analysis services can help assess biomass composition, monitor growth and harvest timing, optimize bioprocessing and biorefinery processes, characterize chemical composition, and screen new sources of biologically active compounds. In addition to its scientific and technical work, the company provides advisory support on contracts and compliance, due diligence, intellectual property strategy, partnerships, funding and financial structuring.